Skip to main content
. 2023 Jun 19;24(1):2223375. doi: 10.1080/15384047.2023.2223375

Figure 3.

(a) Two KM curves showing the difference of OS between patients with and without KRAS mutations, with dot lines presenting the median OS. (b) Two KM curves showing the difference of OS between patients with and without TERT mutations, with dot lines presenting the median OS. (c) Two KM curves showing the difference of OS between young and old patients, with dot lines presenting the median OS. (d) Three KM curves showing the difference of OS across young and old patients with and/or without KRAS/TERT mutations, with dot lines presenting the median OS.

The association of overall survival (OS) with baseline clinical and genetic characteristics.

(a) Altered KRAS gene was associated with inferior OS. Median OS (mOS): 17.8 vs. 33.6 months, hazard ratio (HR): 1.96, 95% confidence interval (CI): 1.37–2.80. (b) Altered TERT gene was associated with inferior OS. mOS: 16.9 vs. 32.7 months, HR: 2.03, 95% CI: 1.22–3.38. (c) Older patient age was not significantly associated with OS. mOS: 30.8 vs. 36.1 months, HR: 1.11, 95% CI: 0.71–1.73. (d) Old patients without altered KRAS or TERT mutations had similar OS in comparison with young patients without KRAS or TERT mutations, while old patients harboring KRAS or TERT alterations had inferior OS (mOS: 17.8 vs. 33.9 months, HR: 2.07, 95% CI: 1.52–2.83; mOS: 17.8 vs. 36.1 months, HR: 2.06, 95% CI: 1.23–3.45).